You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.
SBC: Vova Ida, LLC Topic: 999SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting endothelial arginase to treat diabetes-associated vascular dysfunction
SBC: ARGINETIX, INC. Topic: NHLBIDESCRIPTION (provided by applicant): The product that will result from this STTR is ABH (2(S)-amino-6-boronohexanoic acid), a potent small molecule inhibitor of the enzyme arginase, for treating vascular complications of diabetes. There are 20.8 million Americans with diabetes. More than 65% of these people will die from heart disease or stroke. Men with diabetes are twice as likely, and women wi ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Lentiviral gene therapy for mucopolysaccharidosis
SBC: LENTIGEN CORPORATION Topic: NIDDKDESCRIPTION (provided by applicant): Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive inherited disorder caused by absence of iduronate-2-sulfatase, resulting in systemic accumulation of glycosaminoglycans heparan sulphate and dermatan sulphate. Affected individuals suffer from skeletal abnormalities, organomegaly, life- threatening obstructive airway disease, and, ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice
SBC: Yecuris Corporation Topic: NCRRDESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule targeting of NADPH oxidase in neutrophils
SBC: P2D, INC Topic: NHLBIDESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.
SBC: Oncoimmune Inc Topic: 100Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Rapid Development of a Highly Specific Dengue Diagnostic Test
SBC: Z-Quick, LLC Topic: NIAIDProject Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: R41Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Distributed REMD Simulation for Probing Alzheimer Molecular Mechanisms
SBC: PARABON COMPUTATION, INC. Topic: NIADESCRIPTION (provided by applicant): PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors
SBC: SIXONE SOLUTIONS, LLC Topic: NCIDESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health